Goldman Sachs’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-25,367
| Closed | -$14.1K | – | 6360 |
|
|
2022
Q4 | $14.1K | Sell |
25,367
-49,375
| -66% | -$42K | ﹤0.01% | 5730 |
|
|
2022
Q3 | $89K | Sell |
74,742
-157,718
| -68% | -$170K | ﹤0.01% | 5715 |
|
|
2022
Q2 | $147K | Buy |
232,460
+26,345
| +13% | +$20.2K | ﹤0.01% | 5743 |
|
|
2022
Q1 | $235K | Sell |
206,115
-35,769
| -15% | -$42.7K | ﹤0.01% | 5801 |
|
|
2021
Q4 | $544K | Buy |
241,884
+32,481
| +16% | +$81.5K | ﹤0.01% | 5314 |
|
|
2021
Q3 | $716K | Buy |
209,403
+157,770
| +306% | +$486K | ﹤0.01% | 4982 |
|
|
2021
Q2 | $154K | Sell |
51,633
-45,092
| -47% | -$143K | ﹤0.01% | 5841 |
|
|
2021
Q1 | $312K | Buy |
96,725
+18,785
| +24% | +$62.7K | ﹤0.01% | 5409 |
|
|
2020
Q4 | $165K | Buy |
77,940
+23,518
| +43% | +$38.8K | ﹤0.01% | 5156 |
|
|
2020
Q3 | $64K | Buy |
+54,422
| New | +$55.9K | ﹤0.01% | 5154 |
|
|
2018
Q4 | – | Sell |
-33,778
| Closed | -$92K | – | 5790 |
|
|
2018
Q3 | $92K | Sell |
33,778
-51,084
| -60% | -$106K | ﹤0.01% | 5162 |
|
|
2018
Q2 | $162K | Buy |
84,862
+7,217
| +9% | +$14.6K | ﹤0.01% | 5062 |
|
|
2018
Q1 | $163K | Sell |
77,645
-72,730
| -48% | -$156K | ﹤0.01% | 5087 |
|
|
2017
Q4 | $305K | Buy |
150,375
+75,980
| +102% | +$158K | ﹤0.01% | 5169 |
|
|
2017
Q3 | $99K | Sell |
74,395
-171,839
| -70% | -$213K | ﹤0.01% | 6064 |
|
|
2017
Q2 | $387K | Buy |
246,234
+105,497
| +75% | +$203K | ﹤0.01% | 5299 |
|
|
2017
Q1 | $455K | Sell |
140,737
-72,865
| -34% | -$179K | ﹤0.01% | 5117 |
|
|
2016
Q4 | $288K | Buy |
213,602
+12,468
| +6% | +$16.3K | ﹤0.01% | 5521 |
|
|
2016
Q3 | $314K | Buy |
201,134
+35,258
| +21% | +$54.2K | ﹤0.01% | 5446 |
|
|
2016
Q2 | $221K | Sell |
165,876
-1,467,369
| -90% | -$6.86M | ﹤0.01% | 5618 |
|
|
2016
Q1 | $8.61M | Sell |
1,633,245
-1,290,521
| -44% | -$7.9M | ﹤0.01% | 2336 |
|
|
2015
Q4 | $23M | Sell |
2,923,766
-2,462,774
| -46% | -$21.2M | 0.01% | 1663 |
|
|
2015
Q3 | $45.5M | Sell |
5,386,540
-206,635
| -4% | -$1.91M | 0.02% | 1127 |
|
|
2015
Q2 | $61.2M | Buy |
5,593,175
+1,906,476
| +52% | +$24.5M | 0.02% | 970 |
|
|
2015
Q1 | $51.5M | Buy |
3,686,699
+903,292
| +32% | +$13.8M | 0.02% | 1081 |
|
|
2014
Q4 | $47M | Sell |
2,783,407
-366,619
| -12% | -$5.34M | 0.01% | 1154 |
|
|
2014
Q3 | $42.3M | Sell |
3,150,026
-240,674
| -7% | -$2.87M | 0.01% | 1199 |
|
|
2014
Q2 | $43.2M | Sell |
3,390,700
-279,105
| -8% | -$2.91M | 0.01% | 1208 |
|
|
2014
Q1 | $43.6M | Buy |
3,669,805
+549,609
| +18% | +$7.38M | 0.01% | 1155 |
|
|
2013
Q4 | $43.1M | Buy |
3,120,196
+1,346,667
| +76% | +$19M | 0.01% | 1157 |
|
|
2013
Q3 | $30.9M | Buy |
1,773,529
+476,166
| +37% | +$9.12M | 0.01% | 1300 |
|
|
2013
Q2 | $21M | Buy |
+1,297,363
| New | +$40.1M | 0.01% | 1517 |
|
Other funds holding INFI
BI
SFM
CC
E
Goldman Sachs's INFI Position: Q1 2023 in Review
Goldman Sachs sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q1 2023, closing a stake of 25,367 shares — an estimated $14.1K sold.
Goldman Sachs first reported a position in INFI in Q2 2013 and held it in 32 quarters. The position peaked at $61.2M in Q2 2015. 53 funds tracked by Wall St. Rank hold INFI as of Q1 2023.
- Goldman Sachs reported no remaining Infinity Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- Goldman Sachs sold 25,367 Infinity Pharmaceuticals, Inc. shares in Q1 2023, an estimated $14.1K.
- Goldman Sachs first reported a position in Infinity Pharmaceuticals, Inc. in Q2 2013 and held it in 32 quarters.
- Goldman Sachs's Infinity Pharmaceuticals, Inc. position peaked at $61.2M in Q2 2015.
- 53 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q1 2023.
Based on Goldman Sachs's 13F filing for Q1 2023, filed 11 May 2023.